JP2022547061A5 - - Google Patents

Info

Publication number
JP2022547061A5
JP2022547061A5 JP2022514608A JP2022514608A JP2022547061A5 JP 2022547061 A5 JP2022547061 A5 JP 2022547061A5 JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022547061 A5 JP2022547061 A5 JP 2022547061A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical product
human anti
product according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022514608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/074714 external-priority patent/WO2021043955A1/en
Publication of JP2022547061A publication Critical patent/JP2022547061A/ja
Publication of JP2022547061A5 publication Critical patent/JP2022547061A5/ja
Priority to JP2025097923A priority Critical patent/JP2025148350A/ja
Withdrawn legal-status Critical Current

Links

JP2022514608A 2019-09-05 2020-09-04 進展型小細胞肺癌(es-sclc)の治療のための組成物及び方法 Withdrawn JP2022547061A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025097923A JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌(es-sclc)の治療のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962896224P 2019-09-05 2019-09-05
US62/896,224 2019-09-05
PCT/EP2020/074714 WO2021043955A1 (en) 2019-09-05 2020-09-04 Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025097923A Division JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌(es-sclc)の治療のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2022547061A JP2022547061A (ja) 2022-11-10
JP2022547061A5 true JP2022547061A5 (cg-RX-API-DMAC7.html) 2023-09-11

Family

ID=72521575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514608A Withdrawn JP2022547061A (ja) 2019-09-05 2020-09-04 進展型小細胞肺癌(es-sclc)の治療のための組成物及び方法
JP2025097923A Pending JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌(es-sclc)の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025097923A Pending JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌(es-sclc)の治療のための組成物及び方法

Country Status (10)

Country Link
US (2) US12012453B2 (cg-RX-API-DMAC7.html)
EP (1) EP4025249A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022547061A (cg-RX-API-DMAC7.html)
KR (1) KR20220058601A (cg-RX-API-DMAC7.html)
CN (1) CN114340673A (cg-RX-API-DMAC7.html)
AU (2) AU2020342713A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151838A1 (cg-RX-API-DMAC7.html)
IL (1) IL290834A (cg-RX-API-DMAC7.html)
TW (1) TWI907357B (cg-RX-API-DMAC7.html)
WO (1) WO2021043955A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255817A (zh) * 2022-03-28 2025-01-03 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
TW202602492A (zh) * 2024-04-05 2026-01-16 瑞典商阿斯特捷利康公司 局限期小細胞肺癌之治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3747472B1 (en) * 2015-09-15 2024-04-03 Acerta Pharma B.V. Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
US10975155B2 (en) * 2016-05-13 2021-04-13 Medimmune, Llc CD40L-Fc fusion polypeptides and methods of use thereof
SG11201909064RA (en) * 2017-03-30 2019-10-30 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
TWI890148B (zh) * 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法

Similar Documents

Publication Publication Date Title
EP3458053B1 (en) Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
US12295962B2 (en) Polymorphic compounds and uses thereof
JP2023551559A5 (cg-RX-API-DMAC7.html)
JP2022543062A5 (cg-RX-API-DMAC7.html)
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
EP4512421A1 (en) Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
JP2019516767A (ja) 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ
US20210353648A1 (en) Grapiprant unit dosage forms
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2024539476A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
JP2024521105A5 (cg-RX-API-DMAC7.html)
CN115052628A (zh) 抗pd-1抗体在治疗肿瘤中的用途
JP2021530502A5 (cg-RX-API-DMAC7.html)
JP2011506607A5 (cg-RX-API-DMAC7.html)
JP2022514561A5 (cg-RX-API-DMAC7.html)
JP2024503379A5 (cg-RX-API-DMAC7.html)
JP7824627B2 (ja) 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
JP2023500480A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2025526402A5 (cg-RX-API-DMAC7.html)
TW202428254A (zh) 用於治療晚期實性瘤之組成物及方法
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合